Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

Clinical Immunology

Volumn 137, Issue 1, 2010, Pages 21-30

  Orange, Jordan S ^a   Grossman, William J ^b   Navickis, Roberta J ^c   Wilkes, Mahlon M ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c Hygeia Associates   (United States)

Author keywords

Common variable immunodeficiency; Dose; Incidence; Intravenous immunoglobulin; IVIG; Meta analysis; Pneumonia; Primary immunodeficiency; Trough concentration; X linked agammaglobulinemia

Indexed keywords

ANTIBIOTIC AGENT; CARIMUNE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTRAGLOBIN; NORDIMMUNE; UNCLASSIFIED DRUG;

AGAMMAGLOBULINEMIA; ARTICLE; ATAXIA TELANGIECTASIA; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DRUG DOSE INCREASE; FOLLOW UP; HUMAN; HYPERIMMUNOGLOBULINEMIA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; INFECTION RISK; META ANALYSIS; PNEUMONIA; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; MALE; MIDDLE AGED; PNEUMONIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956615735     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.06.012     Document Type: Article

References (42)

1. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
2. Wood P., Stanworth S., Burton J., Jones A., Peckham D.G., Green T., et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin. Exp. Immunol. 2007, 149:410-423.
3. Bonilla F.A., Bernstein I.L., Khan D.A., Ballas Z.K., Chinen J., Frank M.M., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann. Allergy Asthma Immunol. 2005, 94:S1-S63.
4. Roifman C.M., Levison H., Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987, 1:1075-1077.
5. Gelfand E.W., Reid B., Roifman C.M. Intravenous immune serum globulin replacement in hypogammaglobulinemia. A comparison of high- versus low-dose therapy. Monogr. Allergy 1988, 23:177-186.
6. Roifman C.M., Gelfand E.W. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr. Infect. Dis. J. 1988, 7:S92-S96.
7. Liese J.G., Wintergerst U., Tympner K.D., Belohradsky B.H. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am. J. Dis. Child. 1992, 146:335-339.
8. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann. Intern. Med. 2001, 135:165-174.
9. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol. Allergy Clin. N. Am. 2008, 28:413-437.
10. Yong P.L., Boyle J., Ballow M., Boyle M., Berger M., Bleesing J., et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin. Immunol. 2010, 135:255-263.
11. Roifman C.M., Berger M., Notarangelo L.D. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol. Allergy Clin. N. Am. 2008, 28:875-876.
12. Bonagura V.R., Marchlewski R., Cox A., Rosenthal D.W. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J. Allergy Clin. Immunol. 2008, 122:210-212.
13. Kainulainen L., Varpula M., Liippo K., Svedström E., Nikoskelainen J., Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J. Allergy Clin. Immunol. 1999, 104:1031-1036.
14. Quartier P., Debré M., De Blic J., de Sauverzac R., Sayegh N., Jabado N., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. Pediatr. 1999, 134:589-596.
15. Busse P.J., Farzan S., Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann. Allergy Asthma Immunol. 2007, 98:1-8.
16. Winkelstein J.A., Marino M.C., Lederman H.M., Jones S.M., Sullivan K., Burks A.W., et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006, 85:193-202.
17. Winkelstein J.A., Marino M.C., Ochs H., Fuleihan R., Scholl P.R., Geha R., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003, 82:373-384.
18. Hanson E.P., Monaco-Shawver L., Solt L.A., Madge L.A., Banerjee P.P., May M.J., et al. Hypomorphic nuclear factor-κB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J. Allergy Clin. Immunol. 2008, 122:1169-1177.
19. Sullivan K.E., Mullen C.A., Blaese R.M., Winkelstein J.A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 1994, 125:876-885.
20. Plebani A., Soresina A., Rondelli R., Amato G.M., Azzari C., Cardinale F., et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin. Immunol. 2002, 104:221-230.
21. Busse P.J., Razvi S., Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J. Allergy Clin. Immunol. 2002, 109:1001-1004.
22. Aghamohammadi A., Moin M., Farhoudi A., Rezaei N., Pourpak Z., Movahedi M., et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol. Med. Microbiol. 2004, 40:113-118.
23. Pourpak Z., Aghamohammadi A., Sedighipour L., Farhoudi A., Movahedi M., Gharagozlou M., et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J. Microbiol. Immunol. Infect. 2006, 39:114-120.
24. Church J.A., Leibl H., Stein M.R., Melamed I.R., Rubinstein A., Schneider L.C., et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J. Clin. Immunol. 2006, 26:388-395.
25. Stein M.R., Nelson R.P., Church J.A., Wasserman R.L., Borte M., Vermylen C., et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J. Clin. Immunol. 2009, 29:137-144.
26. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin. Immunol. 2004, 112:1-7.
27. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 1987, 9:1-30.
28. Bayrakci B., Ersoy F., Sanal O., Kilic S., Metin A., Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk. J. Pediatr. 2005, 47:239-246.
29. Ammann A.J., Ashman R.F., Buckley R.H., Hardie W.R., Krantmann H.J., Nelson J., et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin. Immunol. Immunopathol. 1982, 22:60-67.
30. Schiff R.I., Rudd C., Johnson R., Buckley R.H. Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage. Clin. Immunol. Immunopathol. 1984, 31:13-23.
31. Chapel H.M., Spickett G.P., Ericson D., Engl W., Eibl M.M., Björkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol. 2000, 20:94-100.
32. Berger M., Pinciaro P.J. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J. Clin. Immunol. 2004, 24:389-396.
33. Ochs H.D., Pinciaro P.J. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J. Clin. Immunol. 2004, 24:309-314.
34. Berger M. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J. Clin. Immunol. 2007, 27:628-633.
35. Berger M., Cunningham-Rundles C., Bonilla F.A., Melamed I., Bichler J., Zenker O., et al. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J. Clin. Immunol. 2007, 27:503-509.
36. Krasovec S., Ornani A., Oleastro M., Rosenzweig S., Roy A., Perez L., et al. Efficacy and tolerability of an Argentine intravenous immunoglobulin in pediatric patients with primary immunodeficiency diseases. J. Clin. Immunol. 2007, 27:227-232.
37. Chapel H., Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br. J. Haematol. 2009, 145:709-727.
38. M.E. Rose, D.M. Lang, Evaluating and managing hypogammaglobulinemia, Cleve. Clin. J. Med. 73 (2006) 133-137, 140, 143-134.
39. Shehata N., Palda V., Bowen T., Haddad E., Issekutz T.B., Mazer B., et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus. Med. Rev. 2010, 24(Suppl 1):S28-S50.
40. Notarangelo L.D., Plebani A., Mazzolari E., Soresina A., Bondioni M.P. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration 2007, 74:264-275.
41. Rich A.L., Le Jeune I.R., McDermott L., Kinnear W.J. Serial lung function tests in primary immune deficiency. Clin. Exp. Immunol. 2008, 151:110-113.
42. Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int. Immunopharmacol. 2003, 3:1325-1333.